This page contains exclusive content for the member of the following sections: TTS, CTS, IPITA, ISODP, IXA, ITA, TID, IHCTAS, IPTA. Log in to view.

Hepatitis C and Renal Transplantation in the Era of New Antiviral Agents

164.1 - Hepatitis C and Renal Transplantation in the Era of New Antiviral Agents

Presenter: José Maria, Morales, Madrid, Spain
Authors: José Maria Morales


Jose M Morales is Professor of Medicine and currently Consultant Investigator in the Research Institute of Hospital 12 de Octubre of Madrid, Spain. He is Past-President of the Madrid Transplantation Society and Past- Chief of Renal Transplant Program in Hospital 12 de Octubre. His main clinical and investigational activity has been focused on renal transplantation, especially Hepatitis C and immunosuppression, publishing more than 250 peer-review papers (H-index 38). He is a member of the experts who developed the KDIGO guidelines for Hepatitis C in chronic kidney disease in 2008 and 2017. He is the Vice-Chair of the 27th Congress of the Transplantation Society that will be held in Madrid 30 June-5 July, 2018.


Hepatitis C infection after renal transplantation can induce severe liver disease and lower patient and graft survival in HCV-infected compared with HCV negative patients. The successful use of new direct-acting antivirals for hepatitis C is changing the landscape of this complication in renal transplant patients. Therefore, if these drugs become available for all patients and their use is not restricted by the cost, probably Hepatitis C will not be a problem and will show excellent results after renal transplantation worldwide.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6